![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
I recently received a tip on CARN. They are based in Irving, Texas, and specialize in the development of carbohydrare-based therapeutics for the treatment of major illnesses and wounds. They have a new product line (DiaB), which is targeted for diabetics who suffer from lower extermety ulcers. The stock has been beaten down to all-time lows, (sub-$10), yet insiders are purchasing large blocks of the stock. The stock has traded as high as $50/share. Does anyone follow this comppany, and if so, what are the prospects for the new product line and other develpomental drugs that they may have in the pipeline? Good luck, and good investing! DD | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |